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Highly active antiretroviral therapy (HAART) has restricted HIV-
linked mortality and morbidity.[1] Unfortunately, in some patients 
HAART has been associated with adverse drug toxicity such as 
symptomatic hyperlactataemia (SHL) or lactic acidosis (LA). SHL 
and LA are related to the use of nucleoside reverse transcriptase 
inhibitors (NRTIs), occurring most frequently with zalcitabine, 
stavudine (d4T), didanosine, zidovudine (AZT), and lamivudine 
and least frequently with abacavir/tenofovir.[2] These NRTI side-
effects are implicated in mitochondrial toxicity, possibly because 
of their capacity to impede human mitochondrial DNA (mtDNA)
polymerase-γ, which is responsible for the replication of the 16,569 
bp mitochondrial genome.[3] The 140 kDa catalytic protein is 
translated from the 22 exons of the POLG1 gene on chromosome 
15q25, and possesses both polymerase and 3´ - 5´ exonuclease 
activities.[4] Primary mutations in the POLG1 gene lead to secondary 
defects in the maintenance of the mitochondrial genome, depletion 
of mtDNA,[5,6] damage to oxidative phosphorylation[6] and elevation 
of serum lactate,[5,7] thus making the POLG1 gene a strong candidate 
for NRTI-induced mitochondrial-toxicity-related disorders such 
as hyperlactataemia. Literature reports from developed countries 
suggest an incidence rate for SHL of 5 - 10/1 000 patients per year on 
NRTIs and 1/1 000 patients per year for the very severe form (LA), 
which is associated with a high expected mortality.[8]
In South Africa (SA), SHL/LA incidence appears notably high,[9-15] 
especially in KwaZulu-Natal (KZN) Province, which is predominantly 
inhabited by the SA Zulu-speaking population.[10,12,14] The objective of 
this study was to detect if known mutations in mtDNA polymerase-γ 
(POLG1)[16,17] reported to be associated with mitochondrial toxicity 
are also linked with NRTI-induced SHL/LA in the SA Zulu-speaking 
population.
Methods
Sample and clinical data collection
This case-control study comprised 116 HIV-infected adult (aged 18 - 
50 years) patients already enrolled on antiretroviral (ARV) treatment 
according to the National ARV Treatment Guidelines (2004) of the 
National Department of Health (NDoH) of SA. Patients on ARV 
treatment who experienced SHL/LA were classified as cases, and 
those patients on treatment with stavudine for ≥24 months as part of 
their HAART regimen who did not experience SHL/LA were classed 
as controls. Patients were enrolled on the study on their scheduled 
routine clinical visit at Edendale Hospital, a regional-level public sector 
institution in Pietermaritzburg, SA, between March and August 2014.
For evaluation of the cases enrolled in this study, patients were 
reviewed based on definition of their lactate levels as follows:
• Normal: Documented lactate levels <2 mmol/L
• SHL: Documented lactate levels >4.0 mmol/L but <5.0 mmol/L, 
accompanied by symptoms
• Severe SHL: Documented lactate levels >5.0 mmol/L with severe 
symptoms, and in patients recorded as having decreasing pH
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• Lactic acidosis: Patients with a decreasing pH <7.35 and decreas-
ing bicarbonate <17 mmol/L caused by SHL.[18]
Key baseline and longitudinal data were collected (Table 1) including 
the selected independent variables of age, gender, ethnicity, weight, 
height, body mass index (BMI) and duration of treatment with 
stavudine- or zidovudine-containing regimens. The dependent 
variables were a lactate level >4 mmol/L and acid base status 
(bicarbonate <17 mmol/L).
DNA extraction
Genomic DNA was isolated from 113 of the 116 patients’ blood 
samples using the QIAmp DNA Blood Mini Kit (Qiagen, Germany) 
according to the manufacturer’s instructions. The purity and quantity 
were assessed using a Nano Drop ND-1000 spectrophotometer 
(Rockland, USA). R964C and E1143G POLG1 single-nucleotide 
polymorphisms (SNPs) were determined by allelic discrimination 
real-time polymerase chain reaction (PCR) after a series of numerous 
optimisation reactions using primers and probes (Table 2).
Allelic discrimination PCR
The amplification of both SNPs was performed in duplicate using 
5 - 20 ng/µL of 3 µL genomic DNA in 25 µL reaction volume 
comprising 10 µL of 1XTaqman genotyping PCR Master Mix: 3 µL 
of both POLG1 primers (1 µM), 2 µL of each probe (0.5 µM) and 
2 µL of ddH2O (Qiagen, Germany) for E1143G, and 1 µL of each 
probe (0.25 µM) and 4 µL of ddH2O (Qiagen, Germany) for R964C. 
The PCR amplification and detection, performed on a 7500 Real-
time PCR Applied Biosystems machine (Applied Biosystems, USA), 
entailed initial denaturation at 95°C for 10 minutes, followed by 
40  cycles of denaturation at 92°C for 15 seconds and annealing at 
60°C for 60  seconds. This was also confirmed by resolving on 2% 
(w/v) agarose gel (Figs 1 and 2). 
Nucleotide sequencing
DNA sequencing was performed on 40 randomly selected samples to 
cross-check the accuracy of the genotyping results. The same forward 
and reverse primers (previously used for allelic discrimination real-
time amplification of the R964C and E1143G polymorphisms) were 
used (Table 2). A 50 µL reaction volume was used containing 10 µL 
of genomic DNA (5 - 20 ng/µL), 5 µL of 5X Supertherm reaction 
buffer, 3 µL MgCl2 (25 mM), 4 µL dNTPs (2.5 µM), 4 µL of each 
primer (1 µM), 0.3 µL of SuperthermTaq DNA polymerase (250 U/
µL) and 19.7 µL of ddH20 (Qiagen, Germany). The PCR products 
were purified using glass fibre filters (Roche High PCR Product 
Purification Kit, Germany) according to manufacturer’s protocol and 
sequenced in forward and reverse orientations. Finally, the reaction 
products were reconstituted with 15 µL of Hi-Di formamide (Applied 
Biosystems, USA) and run on the ABI PRISM 310 Genetic Analyzer 
(Applied Biosystems, USA). Alignments of the sequences were 
performed using Genescan Software v3.1.0. (Applied Biosystems, 
USA).
Data analysis
Data were analysed using Stata 13.0 (StataCorp, USA). Gene-wise 
comparisons of R964C and E1143G allele frequencies between 
the case and control groups for each SNP and individual allelic 
association tests for an SNP were assessed using Pearson’s χ2 test or 
Fisher’s exact test. Similarly bivariate (unadjusted) comparisons of 
other categorical independent variables by case/control status were 
Table 1. Demographic and clinical data of patients enrolled in the study
Characteristics Cases (n=59) Controls (n=57) p-value*
Demographics
Age (years), median (IQR) 38 (33 - 45) 33 (28 - 40) 0.0151
Male, n (%) 2 (3.4) 33 (57.9) <0.001
Female, n (%) 57 (96.6) 24 (42.1)
Black ethnicity (Zulu), n/total (%) 59/59 (100.0) 57/57 (100.0) NC
Baseline measurements
Weight baseline (kg), median (IQR) 71.4 (58 - 83) 58 (53 - 68) 0.0001
Weight (kg), n/total (%)     
<55 10/57 (17.5) 18/53 (34) <0.001
55 - <60 7/57 (12.3) 10/53 (18.9)
60 - <65 5/57 (8.8) 7/53 (13.2)
65 - <70 4/57 (7.0) 9/53 (17.0)
70 - <75 8/57 (14.0) 6/53 (11.3)
 ≥75 23/57 (40.4) 3/53 (5.7)
BMI (kg/m2) baseline, median (IQR) 29 (24.6 - 32.9) 20.7 (19.5 - 26.3) 0.0017
BMI category, n/total (%)          
Underweight (10 - 18.5 kg/m2) 1/25 (4.0) 2/16 (12.5) 0.0890
Healthy (18.6 - 25 kg/m2) 7/25 (28.0) 9/16 (56.3)
Overweight (25.1 - 30 kg/m2) 7/25 (28.0) 4/16 (25.0)
Obese (30.1 - 40 kg/m2) 9/25 (36.0) 1/16 (6.3)
Very obese (40.1 - 70 kg/m2) 1/25 (4) 0/16 (0)
Baseline laboratory results
CD4+ T-cell count baseline cells/µL, median (IQR) 121 (56 - 156) 89 (26 - 170) 0.3388
Duration on stavudine months, median (IQR) 11 (8.0 - 14.0) 68 (49.0 - 79.5) <0.001
NC = not calculated. 
*Wilcoxon rank-sum (Mann-Whitney U) test used to compare ranks (medians) by group, Pearson’s χ2 test used to compared categorical variables by group.
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performed using Pearson’s χ2 test or Fisher’s exact test. Bivariate 
comparisons of medians of continuous independent variables by 
case/control status were performed using Wilcoxon’s rank-sum test. 
Finally, a multivariable adjusted logistic regression model was also 
developed to assess variables associated with case/control status to 
adjust for confounding and to estimate adjusted odds ratios (AORs). 
A p-value of <0.05 was considered to indicate possible statistical 
significance.
Results
Clinical data
The cases were diagnosed with hyperlactataemia between 4 and 18 
months on ART, with a median of 11 months (interquartile range 
(IQR) 8 - 14 months). All the cases (n=59) were on stavudine at the 
time of SHL/LA diagnosis. At the point of enrolment to the study, 
42 of the 59 cases (71.2%) were on zidovudine, compared with one 
patient out of 57 (1.8%) in the control group. None of the 116 patients 
had SHL/LA symptoms or relapse at the time of enrolment in the 
study.
Females comprised the majority of cases at 96.6%, compared with 
42.1% in the control group (AOR 24.24, 95% CI 5.14 - 114.25).The 
baseline age of the cases and controls when they initiated ART was 
significantly different (p=0.0151) between the two groups. Median 
CD4 count at baseline was 121 cells/µL (IQR 56 - 156) for the cases 
compared with 89 cells/µL (IQR 26 - 170) for the controls. The 
median CD4 T-cell count at the time of hyperlactataemia diagnosis 
for the cases was 206 (IQR 32 - 538). Other characteristics are presen-
ted in Table 1.
Sixty-two percent of the cases (37/59) had lactate values between 
5 mmol/L and 10 mmol/L and 15% (9/59) had documented lactate 
of >10  mmol/L. The median bicarbonate level was 19.5 mmol/L 
(IQR 17 - 22). It took a median time of 4 months for lactate levels to 
normalise after a median duration of 2 months’ drug holiday (time 
off ARV medication). The most common symptoms were weight 
loss, recorded for 98.3% of the cases, loss of appetite (84.7%) and 
peripheral neuropathy (56.0%) (data not shown). Eighty-five percent 
of the cases had virological suppression at the time of diagnosis, with 
their viral load <400 copies/mL.
Where both weight and height measurements were available 
(23 cases and 18 controls), BMI (kg/m2) was calculated. Only 6.3% 
of the controls had a BMI of ≥30 (obese) compared with 36.0% of 
cases (Table 1). On bivariate and multivariate analysis, female gender 
Table 2. Primers and probes used for allelic discrimination real-time PCR of the R964C and E1143G polymorphisms of POLG
SNP   Sequence PCR product size
C-2890T Forward Primer  5´-GCCAAAATCTTCAACTACG-3´
  Reverse  5´-TGGGTGTTAAAGTGGATG-3´ 180
  Sense-wild Probe CAGCCCTTTGCTGAGCGCTTACTAAT
  Sense-mutant CAGCCCTTTGCTGAGTGCTTACTAAT
A-3428G Forward Primer  5´-TGGCTGTTTGAAGAGTTTG-3´
  Reverse  5´-CGCATACCTGGTCAAGAG-3´ 138
  Antisense-wild Probe CGGTCCTCCTCCCGCACCAG
  Antisense-mutant CGGTCCTCCCCCCGCACCAG
Red font is used to emphasise the change in the sequence.
Table 3. Risk factors associated with SHL/LA confirmed by this study*
                           Bivariate Multivariable adjusted
Variable OR (95% CI) p-value OR (95% CI) p-value
Age 1.04 (1.00 - 1.08) 0.078 1.03 (0.98 - 1.09) 0.184
Female 39.19 (8.70 - 176.48) <0.001† 24.24 (5.14 - 114.25) <0.001†
Weight (kg) 1.06 (1.03 - 1.10) <0.001† 1.04 (1.00 - 1.09) 0.035
55 - <60 1.26 (0.37 - 4.34) 0.714
60 - <65 1.29 (0.32 - 5.13) 0.722
65 - <70 0.80 (0.20- 3.27) 0.756
70 - <75 2.4 (0.65 - 8.90) 0.19
 ≥75 13.8 (3.3 - 57.67) <0.001†
CD4+ 107/116 (92%) 1 (1.00 - 1.01) 0.447  1 (0.99 - 1.00) 0.421
Duration on stavudine (months) 0.57 (0.35 - 0.93) 0.025
Viral load 19/116 (16%) 1 (1.00 – 1.00) 0.46      
*Note some variables not retained in final multivariable model owing to large numbers of missing observations for these variables which would have reduced the overall data matrix for the model.
†p <0.05.
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(AOR  24.24, 95% CI 5.14 - 114.25, p<0.001) and high initiating 
body weight (OR 13.80, 95% CI 3.30 - 57.67, p=0.001) remained 
significantly asso ciated with SHL/LA (Table 3).
Allelic discrimination PCR and sequencing
According to the allelic discrimination real-time PCR amplification 
assay employed for screening of the polymorphisms, out of the 113 
samples of sufficient yield and purity, none appeared to have either 
the variant allele T for the R964C or variant allele G for the E1143G 
monogenic polymorphisms, in their POLG1 gene. Subsequent 
confirmation of the genotypes with sequencing had similar outcomes 
(Table 4) and no inconsistencies were illustrated between the two 
analytical approaches (Figs 1 - 4).
No significant association between the R964C and E1143G 
polymorphisms with hyperlactataemia disease was established; 
neither the cases nor the controls had any R964C and E1143G variant 
alleles or the homozygous variant genotypes (Table 4 and Figs 3 - 4). 
These findings suggest that association of these known monogenic 
POLG1 mutations with SHL/LA in the Zulu-speaking SA population 
is not common.
Discussion
Of the 116 HIV-positive patients, concerns of intolerance to first-
line therapy because of mitochondrial toxicity were significant 
for the 59  cases on stavudine therapy that were diagnosed with 
hyper lactataemia between 4 and 18 months, with a median range 
of 11  months. This period to diagnosis was consistent with larger 
cohorts in similar settings.[9,19,20] All the cases (n=59) were on 
stavudine therapy at the time of SHL/LA diagnosis and the controls 
(n=56) had been on stavudine for ≥24 months. At the time of 
enrolment in the study, none of the cases was on stavudine compared 
with the controls (21/57). Eleven months of exposure to stavudine in 
the cases compared with 68 months in the controls (p<0.001) clearly 
demonstrates that the use of stavudine poses a risk in the development 
of SHL/LA, as documented by other investigators. [8,9,11,12,14,21] While a 
significant number of the cases (42/59) were on zidovudine treatment 
at the time of enrolment in the study, only one patient among the 
control group (n=57) was on similar treatment.  The 42 cases on 
zidovudine did not show any symptoms or relapse of SHL/LA, 
Fig. 1. Amplification of the R964C SNP in exon 18 of POLG resolved on a 
2% (w/v) agarose gel.
Fig. 2. Amplification of the E1143G SNP in exon 21 of POLG resolved on a 
2% (w/v) agarose gel with molecular size marker.
Table 4. Allele and genotype frequencies for the R964C and E1143G polymorphisms
  POLG1 Cases, n (%) Controls, n (%)
Genotype R964C    
Homozygous wild-type CC 56 (100) 57 (100)
Heterozygous CT 0 0
Homozygous variant TT 0 0
Total   56 57
Genotype E1143G    
Homozygous wild-type AA 56 (100) 57 (100)
Heterozygous AG 0 0
Homozygous variant GG 0 0
Allele frequencies      
Wild-type R964C C allele 56 (100) 57 (100)
Variant T allele 0 0
Wild-type E1143G A allele 56 (100) 57 (100)
Variant G allele 0 0
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indicating that changing from stavudine to zidovudine is linked with 
decreased risk of SHL/LA relapse.[22,23] This strategy has been clearly 
documented in other studies.[9,19]
Female gender, age, high initiating body weight and treatment with 
stavudine were significantly associated with increased risk of SHL/LA. 
These risk factors are consistent with those reported by other studies 
in related settings,[10,12,14] as well as in other studies globally. [8,15,24-26] In 
this study, the baseline age of the cases and controls was significantly 
different (p=0.015), with a median age of 38 (IQR 33 - 45) and 33 
(IQR 28 - 40) years for cases and controls, respectively. This is in good 
agreement with studies that have shown associations between SHL/
LA and advanced age.[24,25] Other studies have reported low baseline 
CD4 count[12,24,26] as a factor associated with SHL/LA. In this study, 
the controls had a lower  baseline CD4 count median, of 89 cells/µL 
(IQR 26 - 170) compared with 121 cells/µL (IQR 56 - 156) in cases, at 
the time of hyperlactataemia diagnosis. Hence it is conceivable from 
this study that there is no association between CD4 count and SHL/
LA among the SA population, in good agreement with the reports of 
Osler and others.[11,27] However, our findings contradict the results 
obtained by some researchers, in which a strong association between 
patient age[25] and CD4 count[24,26] and SHL/LA was observed. Several 
POLG1 mutations have been studied, resulting in deletions or point 
mutations in mtDNA and decreased polymerase activity. Although 
there is a spectrum in the degree of insufficiency in polymerase 
activity, the most severe mutations lead to loss of >99% of poly-
merase function and cell death due to insufficient cellular energy 
production.[28,29]
The pathogenicity of the p.E1143G change, caused by an A-to-G 
substitution at nucleotide position 3428 in exon 21, has been widely 
scrutinised.[28,30,31] The substitution is found at a high frequency in 
control populations (2 - 3%), and has never been identified alone 
in any disease patients.[32] E1143 is a highly conserved amino 
acid located adjacent to motif C of the polymerase domain, and 
biochemical investigations show a possible role in the modular 
expression of other POLG1 mutations in cis.[33]
The POLG1 R964C mutation has been definitively associated 
with hyperlactataemia in an HIV-positive Thai female patient 
undergoing HAART with stavudine.[16] Biochemical analysis 
demonstrated an 86% reduction in activity of recombinant R964C 
POLG1 compared with that of wild-type POLG1. Cultures in 
stavudine patient-derived lymphoblastoid cell lines (LCLs) had 
significantly reduced mtDNA levels compared with the LCLs of 
wild-type POLG1.[16] Further biochemical analysis of the R964C 
holoenzyme showed a 33% decrease in dTTP incorporation 
efficiency and a threefold decreased discrimination for d4TTP 
compared with the wild-type POLG1.[29] Thus, the POLG1 R964C 
mutation may be a cause of SHL caused by NRTI-mitochondrial 
dysfunction. 
The POLG1 mutations associated with NRTI-mitochondrial 
toxicity to date, R964C and E1143G,[16,17] were not seen in any of 
the HIV-positive Zulu-speaking patients we screened. A direct 
relationship between the R964C/E1143G mutation and SHL cannot 
be determined from this study. Previous work has shown that 
neither the R964C nor E1143G POLG1 mutations were present 
among 14 Malawian HIV-positive patients on stavudine HAART. [34] 
Collectively, it can be stipulated that these variants are not common 
among the black African population. However, whether R964C/
E1143G is a true functional mutation cannot be determined from 
this study but is evident in previous studies[16,17] conducted in other 
populations. We cannot exclude the possibility that screening 
a larger number of patients would have shown some cases of 
POLG1 mutation associated with NRTI mitochondrial toxicity 
and SHL. Further, we only tested for two of the >20 described 
POLG1 mutations, so we are unable to exclude the possibility that 
mutations other than those that we tested for are associated with 
SHL and could explain the high incidence of stavudine-induced 
SHL/LA in the Zulu-speaking population.
Conclusions
This study significantly confirms the use of stavudine, female 
gender, age and high initiating baseline weight (high BMI) as risk 
factors for the development of SHL/LA, specific for the Zulu ethnic 
group. Similar factors have been reported by other investigators in 
both local and international settings.[10,12,14,24]
The R964C and E1143G polymorphisms within POLG1 were 
not observed in this study population. The study confirms that 
Fig. 3. Electropherogram plot of sequencing analysis of sample 26 forward primer of E1143G SNP of POLG.
Fig. 4. Electropherogram plot of sequencing analysis of sample 3 reverse primer of R964C SNP of POLG.
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R964C, E1143G or both polymorphisms do not have a link to an 
increased risk of developing SHL/LA in stavudine-treated HIV-
infected Zulu-speaking patients. These findings are similar to the 
outcomes described by other investigators testing similar mutations 
in Malawi, on a black African population.[34] Collectively, it can be 
stipulated that these variants are not common among the black 
population.
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